Peter Greenleaf

Peter Greenleaf

Former Chief Executive OfficeratAurinia Pharmaceuticals· In proxies 2021–2025

Pay in FY2025-9% from the year before · Aurinia Pharmaceuticals stock +77.6% the same year

Peter Greenleaf was paid $5.9M in FY2025 (Dec), down 9%. Aurinia Pharmaceuticals stock rose 77.6% that year.

Pay$100 in the stock at the end of FY20 → $115
Pay is from the Summary Compensation Table of each Aurinia Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Aurinia PharmaceuticalsPublic company · 5 yr
    • Former Chief Executive Officer2021 – Present · 5 yrStock in role +22%
  2. Antares Pharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. BioDelivery Sciences International, IncPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Aurinia PharmaceuticalsDirector · 4 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?